Challenges and opportunities in TILs and TCR modified cell therapies [Video]

Sebastian Klobuch, PhD, Netherlands Cancer Institute, Amsterdam, The Netherlands, gives an overview of hurdles in the development of tumor-infiltrating lymphocytes (TILs) and T cell receptor (TCR) modified cell therapies. Toxicity, especially IL-2 related toxicity, and patient selection are current issues surrounding TILs, but there are opportunities to use TILs in indications other than melanoma, such as lung cancer. More research is needed to enable TCR modified cell therapies to target more than one antigen and overcome the oppressive tumor microenvironment. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.